Clinical Trial Update: Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating darolutamide for testosterone-driven salivary gland cancers is active but not currently recruiting. The study encompasses locally adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Carcinoma
• Unresectable Salivary Gland Carcinoma

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING